4023 results about "Macrophage cell" patented technology

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

To provide a technique for enhancing the dermal delivery of a composition and, furthermore, enhancing the delivery of the composition to macrophage-surrounding areas.SOLUTION: The present invention provides a liposome with a particle diameter of 300 nm or less, comprising (A) polyglycerin fatty acid ester, (B) phospholipid, and (C) sterol. In a preferred embodiment, the liposome further comprises (D) an amphiphilic molecule having a disaccharide-to-trisaccharide hydrophilic group and an alkyl-chain hydrophobic group within its molecular structure.SELECTED DRAWING: None

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The invention relates to a bone organ constructed based on oxygen-releasing immune hydrogel microspheres and a preparation method and application thereof. An oxygen release material, macrophages and bone marrow mesenchymal stem cells are loaded in the oxygen release immune hydrogel microspheres. And adding the oxygen-releasing immune hydrogel microspheres into a culture medium for culturing to obtain the bone organ constructed based on the oxygen-releasing immune hydrogel microspheres. The oxygen release material (CaO2-HAp) is entrapped in the hydrogel microspheres, so that continuous oxygen supply can be provided in a defect area, the low-oxygen environment is improved, the activity of osteoblasts is improved, osteogenic differentiation is promoted, macrophages are entrapped by the microspheres, the immune microenvironment is regulated and controlled, the release of proinflammatory cytokines is reduced, the osteogenic efficiency is improved, and bone defect repair is accelerated. The micro-fluidic technology is utilized to accurately control the size and shape of the microspheres, so that the microspheres can adapt to irregular bone defects, bone organs are formed through long-term in-vitro culture, and the biological activity and adaptability of the bone repair material are improved.

The invention discloses multifunctional hydrogel and application thereof, and belongs to the technical field of biological medicine. According to the multifunctional hydrogel, ketal mercaptan with two hydrazide ends and oxidized dextran are cross-linked to form a cross-linked network containing dynamic covalent bonds. The preparation method comprises the following steps: dissolving ketal mercaptan with two hydrazide ends in deionized water to obtain a ketal mercaptan solution, dissolving oxidized dextran in deionized water to obtain an oxidized dextran solution, mixing the ketal mercaptan solution with the oxidized dextran solution, and standing to obtain the multifunctional hydrogel. The multifunctional hydrogel has pH / ROS dual responsiveness, can respond to inflammation microenvironment and low pH of infectious wounds, remove active oxygen, release therapeutic drugs, regulate macrophage polarization and relieve bacterial infection, thereby playing a key role in inflammation, proliferation and remodeling stages of wound healing to accelerate wound healing. The curcumin-encapsulated liposome is added into the multifunctional hydrogel, so that the antibacterial effect can be further improved.

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.

The invention relates to protein nanoparticles for treating ulcerative colitis as well as a preparation method and application thereof, and relates to the field of nano pharmaceutical preparations. 5-aminosalicylic acid is encapsulated in zein to achieve the purpose of improving the bioavailability of the 5-aminosalicylic acid by preparing protein nanoparticles of a targeted inflammation colon part, mannose grafted hyaluronic acid is used as a stabilizer to be attached to the surfaces of the zein nanoparticles through electrostatic adsorption and hydrogen-bond interaction, and the bioavailability of the 5-aminosalicylic acid is improved. Mannose can be targeted to immune cells through a mannose receptor, and can be cooperated with 5-aminosalicylic acid to treat ulcerative colitis. The hyaluronic acid has the effects of stabilizing the protein nanoparticles and targeting macrophages and intestinal epithelial cell CD44 receptors in ulcerative colitis tissues, so that aggregation of the nanoparticles in the colitis tissues is mediated, the protein nanoparticles have the functions of resisting inflammation, resisting oxidation and repairing barrier injury, and a new research direction is provided for treatment of ulcerative colitis.

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

A compound bacterial powder preparation, and a preparation method therefor and the use thereof. The compound bacterial powder preparation comprises Bifidobacterium animalis, Lactiplantibacillus plantarum and Bacillus coagulans, wherein the deposit number of the Bifidobacterium animalis strain is CGMCC No.25681. The compound bacterial powder preparation can stimulate macrophage RAW264.7 of a mouse to generate cell factors TNF-α and IL-6, thereby enhancing immunity; can significantly enhance the cellular immune function, the humoral immune function and the mononuclear-macrophage function of a mouse, and has the function of enhancing immunity; and can increase the ink propelling rate and has the functional potential of relaxing the bowels.

The invention discloses a CA9-targeted chimeric antigen receptor and application thereof, and belongs to the technical field of biological medicines. The CA9 targeting chimeric antigen receptor provided by the invention comprises a CD8 alpha leading signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane structural domain and a CD3 zeta intracellular costimulatory signal transduction structural domain. According to the invention, an anti-CA9 single-chain variable fragment is used as an antigen binding structural domain to construct a chimeric antigen receptor (CAR) molecule, the macrophage expressing the anti-CA9CAR can realize specific targeting and phagocytosis killing of CA9 positive kidney cancer cells, and the constructed lipid nanoparticle delivery system can effectively transfer a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the CA9 positive kidney cancer cells can be effectively targeted and killed. The constructed hydrogel-liposome combined drug delivery system has the performance of relieving toxic and side effects, controllable release and hemostasis.

The invention provides a preparation method of cereal fermentation broth postbiotics and application of the cereal fermentation broth postbiotics in improvement of systemic chronic inflammation and reduction of cholesterol and low-density lipoprotein, and belongs to the technical field of fermentation engineering. The invention provides a preparation method of cereal fermentation broth metabiotics, which is characterized in that mixed cereals are used as raw materials, anaerobic fermentation is carried out by using compound enzymes and various bacteria, and polysaccharides and proteins in the cereal raw materials can be quickly converted into functional small molecular substances, such as polypeptides, total phenols and total flavonoids. The cereal fermentation broth metagen can inhibit secretion of a macrophage proinflammatory medium, inhibit generation of inflammatory factors of liver, heart and intestinal tissues, and improve activation of adipose tissue macrophages related to body inflammation. After the cereal fermentation liquor is subjected to post-biogen treatment, glucose and lipid metabolism disorder can be effectively improved, liver function damage can be relieved, and the intestinal barrier function can be effectively improved.

The invention is applicable to the technical field of biological pharmacy, and provides application of a novel nano drug-loading delivery system of exosome-loaded ginsenoside Rh2. The ginsenoside Rh2 and the MSC-derived exosome are subjected to blending ultrasonic treatment to realize exosome drug loading, and a novel Rh2-coated MSC-exo nano drug loading delivery system is synthesized. Animal experiments show that the Rh2 (at) MSC-exo novel nano drug-loading delivery system can be targeted to ectopic intimal lesions and has an inhibition effect; the expression level of an M1 type macrophage marker CD86 is enhanced, and the expression level of an M2 type macrophage marker CD206 is inhibited; the m6A level and the METTL3 expression level of ectopic endometrial tissues are reduced; according to the present invention, RNA-seq and MIP-seq sequencing is adopted to determine that WNT2 is the potential target of the Rh2 (at) MSC-exo novel nanometer drug loading delivery system affecting ectopic inner membrane m6A modification;

The invention discloses a plant lactobacillus JNL0074 strain, application thereof and a microbial agent, and belongs to the technical field of microorganisms. The lactobacillus plantarum JNL0074 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC NO: 31047, and the lactobacillus plantarum is classified and named as lactobacillus plantarum. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention belongs to the technical field of organic chemical synthesis, and particularly relates to a gentiopicroside amide derivative, a synthesis method and application. A series of gentiopicroside amide derivatives are synthesized by taking gentiopicroside as a research object, carrying out structural modification on 6 '-site hydroxyl of gentiopicroside and introducing a benzoyl chloride group into a gentiopicroside structure. The synthetic method has the beneficial effects that on one hand, the synthetic method of the gentiopicroside amide derivative, which is mild in reaction condition and environment-friendly, is established; on the other hand, the 20 synthesized gentiopicroside amide derivatives have a remarkable inhibition effect on expression of LPS-induced THP-1 macrophage IL-6 and STAT3 protein content, the anti-inflammatory activity is remarkable, the action effect is superior to that of parent compound gentiopicroside, and a new thought is provided for preparation of STAT3 small-molecule inhibitors and anti-inflammatory drugs.

The invention discloses an application of an inhibitor aiming at T cell TIGIT in preparation of an anti-tuberculosis drug. The inhibitor comprises an Ociperlimab (Ociperlimab), an AGEN1777 (AGEN1777), a Tiragolumab (Tiragolumab) and the like. The TIGIT on the surface of the T cell is blocked, the T cell is promoted to increase the capacity of eliminating intracellular bacteria of macrophages by up-regulating MPEG1, the proliferation of tubercle bacillus is controlled, and evidence is provided for developing antituberculous drugs.

A bifidobacterium animalis strain, a probiotic formulation, and a preparation method for and a use of the bifidobacterium animalis strain. The bifidobacterium animalis strain has a preservation number of CGMCCNo. 25681. The bifidobacterium animalis strain and the probiotic formulation containing same can produce extracellular polysaccharides, lactic acid and short-chain fatty acid at high yield, stimulate a mouse to generate cytokines TNF-α and IL-6, have an immunity enhancement function, improve the ink propulsion rate, and have a bowel relaxing function; and the single bacterial powder of the bifidobacterium animalis strain can significantly enhance the cellular immune function and the mononuclear-macrophage function of mice.

The invention provides an intracellular mycobacterium tuberculosis in-situ nucleic acid detection method based on CRISPR / Cas and application, and the method comprises the following steps: S1, designing crRNA and a primer pair of a mycobacterium tuberculosis target gene sequence, and synthesizing a single-stranded DNA fluorescent probe; s2, preparing a standard solution containing a target gene sequence, and incubating with a CRISPR / Cas12a system; s3, extracting nucleic acids of different types of bacteria, uniformly mixing the nucleic acids of different types of bacteria with the CRISPR / Cas12a system, and incubating; s4, incubating an attenuated strain of mycobacterium tuberculosis and the DNA fluorescent probe, infecting macrophages, and incubating to obtain infected cells; s5, electrically transferring a CRISPR / Cas12a system into the infected cells in S4 by utilizing an electroporation technology, incubating, and detecting the intensity of a fluorescence signal; and S6, performing quantitative and positioning analysis on the detected fluorescence signal to complete detection, and directly introducing a CRISPR / Cas12a system into the macrophage by adopting an electroporation technology to realize intracellular in-situ detection, thereby avoiding the operation complexity of a nucleic acid extraction link and the loss of detection sensitivity in the prior art.

The invention discloses a strain of lactobacillus pentosus JNL0030, application thereof and a microbial preparation, and belongs to the technical field of microorganisms. The lactobacillus pentosus JNL0030 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO: 31045, and the lactobacillus pentosus is classified and named as lactobacillus pentosus. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention provides a fiber dressing for promoting wound healing and a preparation method and application thereof, and belongs to the technical field of biological materials. The shell of the fiber dressing contains the first medicine for promoting polarization of macrophages, and the first medicine can promote polarization of macrophages at normal and diabetic wound surfaces from M1 type to M2 type; a shell substrate is a mixture of hydrophilic and hydrophobic polymers, so that painless adhesion and stripping of a wound surface can be realized by absorbing seepage and spraying non-irritant normal saline on the wound surface, and secondary injury of the wound surface is reduced; an inner core contains a second medicine and a third medicine which are used for inducing death of M1 type macrophages, so that wound inflammatory response can be reduced, wound bacteria can be killed, wound infection degree can be reduced, and wound healing can be accelerated; the core matrix is a mixture of hydrophilic and hydrophobic polymers with good biocompatibility, can provide mechanical support for the fiber dressing, and provides a slow release effect for the two substances in the core. By controlling the composition of the inner core and the shell, the healing of normal wounds and diabetic wounds can be effectively promoted.

The invention relates to the technical field of atherosclerosis related drugs, in particular to a macrophage membrane functionalized manganese dioxide nano-drug as well as a preparation method and application thereof in treatment of atherosclerosis. The invention relates to a macrophage membrane functionalized manganese dioxide nano-drug, which comprises an HMnO2 carrier, colchicine is loaded on the HMnO2 carrier, and a macrophage membrane is coated outside the HMnO2 carrier. The preparation can be applied to practical operation of preparing medicines for treating atherosclerosis. According to the technical scheme, the technical problem of limited treatment effect caused by single action mechanism of medicines for treating atherosclerosis in the prior art can be solved. The nano-drug in the scheme can remove ROS to play an anti-inflammatory effect, reprogram macrophages and promote cholesterol excretion, and is used for synergistically treating atherosclerosis. The macrophage membrane can target an inflammation part and escape from an immune system. And the side effect of the nano-drug is relatively small, so that the nano-drug has ideal popularization and application prospects.

The invention relates to a culture medium and a culture method of persistent DC-CIK cells and application of the culture medium and the culture method, and belongs to the technical field of cell culture. The invention provides a culture medium for persistent DC-CIK cells, which takes a serum-free culture medium as a solvent and comprises a recombinant human granulocyte macrophage colony stimulating factor, a recombinant human interleukin-12, a recombinant human tumor necrosis factor-alpha, a recombinant human interferon-gamma, L-cysteine, glutathione, ginseng polysaccharide and streptomycin sulfate. According to the culture medium and the culture method of the persistent DC-CIK cells, proliferation and growth of the DC-CIK cells can be promoted, and very high tumor killing activity of the DC-CIK cells can be maintained for a long time.

The invention provides a nano photosensitizer modified by outer membrane vesicles of genetically engineered bacteria as well as a preparation method and application of the nano photosensitizer. The nano photosensitizer is a nano material with the particle size of 80-120 nm, and the nano photosensitizer modified by the genetically engineered bacterium outer membrane vesicle comprises dipalmitic acid phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), dioleoyl lecithin (DOPC), cholesterol, a small molecule dye and CD47nb-OMV membrane protein. The chemical structure of the small molecule dye is shown as a formula I or a formula II. The nano photosensitizer OBDlp modified by outer membrane vesicles of genetically engineered bacteria serves as a novel nano photosensitizer, tumor targeting PTT is mediated through NIR II FL / PA imaging, tumor immunogenicity is improved, antigen presenting cells are activated, and infiltration and functionalization of CD8 + T cells are caused. And OBDlp and laser are combined to induce release of a large amount of DAMPs and trigger ICD to promote maturation of cDC1s. Meanwhile, a CD47 nano antibody carried by the nano photosensitizer induces polarization of M1 phenotype macrophages by blocking a CD47-SIRP alpha signal transduction axis, and an immunosuppression tumor microenvironment is reversed.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

Provided are compositions comprising a HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or a protein comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Methods of osteogenesis are provided, including, for example, methods of enhancing bone repair, modulating polarization of macrophages with proinflammatory and anti-inflammatory activity and bone resorption of osteoclasts, and methods of treating inflammatory diseases, spinal cord injury, liver and kidney diseases, cardiovascular diseases, diabetes, post-menopausal syndrome, infertility, or hematopoietic diseases, or enhancing wound healing.

The invention discloses a PEI and targeting peptide modified magnetic nano-carrier and a preparation method and application thereof. The nano-carrier is regular in morphology and uniform in particle size and has good crystallinity and magnetic performance. E5 polypeptide and RGD cyclic peptide on the surface of the nano-carrier are respectively combined with CXCR4 protein and integrin on the surface of a tumor cell, and the nano-carrier and CXCR4 are internalized into lysosome through an integrin-mediated way, so that the target protein CXCR4 is degraded. The PEI in the nano-carrier can load and deliver siRNA into tumor cells to silence the expression of CXCR4 mRNA (messenger Ribonucleic Acid). Through nucleic acid delivery and a protein targeted degradation strategy, the CXCR4 level of tumor cells is jointly reduced, the migration ability of the tumor cells is inhibited, and meanwhile, the anti-tumor effect of M1 type polarization of macrophages is activated.

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.

The invention discloses a method for differentiating induced pluripotent stem cells into macrophages. The method comprises the following steps: S1, inducing pluripotent stem cells to form embryoid bodies; s2, differentiating the embryoid body into a monocyte with CD14 expression; s3, the mononuclear cells are differentiated into macrophages with CD14 / CD11b expression; and S4, polarizing the macrophages into M1 type macrophages and / or M2 type macrophages. According to the method for differentiating the induced pluripotent stem cells into the macrophages, the cells can be effectively induced to differentiate towards the macrophages, the induced pluripotent stem cells are subjected to directional differentiation culture in a short time to obtain the macrophages, and the generated macrophages express CD14 and CD11b and have remarkable phagocytic activity on yeast glycan. The method is of great significance to large-scale production of macrophages.